Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of >10 μM. The gene discussed is EGFR; the disease is prostate carcinoma.